425: Strive and Semler Scientific Merger: Cautionary Outlook

Strive, Inc. and Semler Scientific, Inc. issue a cautionary statement regarding their proposed business combination, highlighting inherent risks and uncertainties.

Summary

• Strive, Inc. and Semler Scientific, Inc. are engaged in a proposed business combination.
• The communication, reposted by Strive CEO Matthew Cole on November 12, 2025, serves as a cautionary statement regarding forward-looking information related to the transaction.
• Statements about the strategic and financial benefits, timing of closing, and successful integration are considered forward-looking and subject to significant risks and uncertainties.
• Investors are urged to read the Registration Statement on Form S-4 and the Information Statement/Proxy Statement/Prospectus when available for important details about the companies and the proposed transaction.
• Strive will issue additional shares of its Class A common stock in connection with the proposed transaction, which will result in dilution.

Sentiment

Score: 4

Explanation: The filing is primarily a cautionary statement heavily emphasizing risks and uncertainties associated with the proposed business combination, rather than highlighting positive developments or financial performance. While a merger can be positive, the document's tone is focused on potential negative outcomes and procedural requirements.

Negatives

• Strive's issuance of additional shares of its Class A common stock in connection with the proposed transaction will cause dilution.
• The integration of the two companies may be more difficult, time-consuming, or costly than expected.
• The proposed transaction may be more expensive or take longer to complete than anticipated due to unexpected factors or events.
• Management's attention may be diverted from ongoing business operations and opportunities.

Risks

• The occurrence of any event, change, or other circumstances that could give rise to the right of one or both companies to terminate the merger agreement.
• The possibility that the proposed transaction does not close when expected or at all because the conditions to closing are not received or satisfied on a timely basis or at all.
• The outcome of any legal proceedings that may be instituted against Strive, Semler Scientific, or the combined company.
• The possibility that the anticipated benefits of the proposed transaction, including anticipated cost savings and strategic gains, are not realized when expected or at all.
• Risks associated with changes in, or problems arising from, implementation of Bitcoin treasury strategies and risks associated with Bitcoin and other digital assets.
• General economic and market conditions, interest and exchange rates, monetary policy, and laws and regulations and their enforcement could impact anticipated benefits.
• Potential adverse reactions of Strive's or Semler Scientific's customers or changes to business or employee relationships, including those resulting from the announcement or completion of the proposed transaction.
• Changes in Strive's or Semler Scientific's share price before closing.

Future Outlook

The outlook and expectations of Strive and Semler Scientific regarding the proposed transaction, including strategic and financial benefits, the timing of closing, and the ability to successfully integrate the combined businesses, are forward-looking statements. These statements are based on assumptions and are subject to significant risks and uncertainties that could cause actual results to differ materially from anticipated results.

Management Comments

• Matthew Cole, Chief Executive Officer of Strive, Inc., reposted the communication on X.com on November 12, 2025, in connection with the proposed business combination.

Industry Context

na

Legal Proceedings

• The outcome of any legal proceedings that may be instituted against Strive or Semler Scientific or the combined company is a risk factor.

Stakeholder Impact

• Shareholders of Strive will experience dilution due to the issuance of additional Class A common stock.
• Stockholders of Semler Scientific will need to approve the proposed transaction.
• Customers and employees of both Strive and Semler Scientific may have adverse reactions or changes to business or employee relationships as a result of the announcement or completion of the proposed transaction.

Next Steps

• A definitive Information Statement/Proxy Statement/Prospectus will be sent to the stockholders of Semler Scientific to seek their approval of the proposed transaction.
• Investors and stockholders of Semler Scientific are urged to read the Registration Statement and Information Statement/Proxy Statement/Prospectus when they become available, along with any other relevant documents filed with the SEC.

Key Dates

Keywords

Strive, Semler Scientific, merger, acquisition, business combination, SEC filing, Form 425, forward-looking statements, risks, Bitcoin treasury, dilution